{"title":"当慢性病和罕见病的世界交汇在一起","authors":"Asher Mullard","doi":"10.1038/d41573-024-00114-3","DOIUrl":null,"url":null,"abstract":"Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.","PeriodicalId":122,"journal":{"name":"Allergy","volume":null,"pages":null},"PeriodicalIF":12.6000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"When chronic and rare disease worlds converge\",\"authors\":\"Asher Mullard\",\"doi\":\"10.1038/d41573-024-00114-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.\",\"PeriodicalId\":122,\"journal\":{\"name\":\"Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.6000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-024-00114-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00114-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology. Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.
期刊介绍:
Allergy is an international and multidisciplinary journal that aims to advance, impact, and communicate all aspects of the discipline of Allergy/Immunology. It publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors, and correspondences. The journal accepts articles based on their scientific merit and quality.
Allergy seeks to maintain contact between basic and clinical Allergy/Immunology and encourages contributions from contributors and readers from all countries. In addition to its publication, Allergy also provides abstracting and indexing information. Some of the databases that include Allergy abstracts are Abstracts on Hygiene & Communicable Disease, Academic Search Alumni Edition, AgBiotech News & Information, AGRICOLA Database, Biological Abstracts, PubMed Dietary Supplement Subset, and Global Health, among others.